drugset / Trial / NCT05262179
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of CTO0101
Timeline
- Start
- 2021-10-05
- Primary completion
- 2022-05-27
- Completion
- 2022-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTO0101 | Unknown | — | — |
Indications
No indication recorded.